⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1364961 | 1.00 | — | — | |
| SCHEMBL1256601 | 1.00 | — | — | |
| SCHEMBL63812 | 1.00 | — | — | |
| SCHEMBL7412 | 1.00 | — | — | |
| SCHEMBL114870 | 1.00 | — | — | |
| SCHEMBL2025245 | 1.00 | — | — | |
| SCHEMBL8088 | 1.00 | — | — | |
| SCHEMBL200242 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL23391535 | 0.98 | SLC1A2 (0.58) | — | |
| Methane SCHEMBL14937659 | 0.98 | SLC1A2 (0.58) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4076492-A1 | PCSK9 ANTAGONIST COMPOUNDS | Merck Sharp & Dohme LLC (US) | 2022-10-26 | — | — | EP | disclosed |
| WO-2018236928-A1 | HEPATITIS C VIRUS NS3/4A PROTEASE INHIBITORS | UNIVERSITY OF MASSACHUSETTS (US) | 2018-12-27 | — | — | WO | disclosed |
| EP-3226900-A1 | IDENTIFICATION OF VSIG8 AS THE PUTATIVE VISTA RECEPTOR AND ITS USE THEREOF TO PRODUCE VISTA/VSIG8 MODULATORS | Immunext, Inc. (US) | 2017-10-11 | — | — | EP | disclosed |
| WO-2016090347-A1 | IDENTIFICATION OF VSIG8 AS THE PUTATIVE VISTA RECEPTOR AND ITS USE THEREOF TO PRODUCE VISTA/VSIG8 MODULATORS | IMMUNEXT, INC. (US) | 2016-06-09 | — | — | WO | disclosed |
| US-9061959-B2 | Method for manufacturing optically active menthol | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2015-06-23 | — | — | US | disclosed |
| US-9000192-B2 | Catalyst for asymmetric hydrogenation and method for manufacturing optically active carbonyl compound using the same | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2015-04-07 | — | — | US | disclosed |
| EP-2675912-A1 | METHOD FOR ASSAYING OGFOD1 ACTIVITY | Isis Innovation Ltd (GB) | 2013-12-25 | — | — | EP | disclosed |
| EP-2647616-A1 | METHOD FOR MANUFACTURING OPTICALLY ACTIVE MENTHOL | Takasago International Corporation (JP) | 2013-10-09 | — | — | EP | disclosed |
| US-20130253228-A1 | METHOD FOR MANUFACTURING OPTICALLY ACTIVE MENTHOL | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2013-09-26 | — | — | US | disclosed |
| US-20130217895-A1 | CATALYST FOR ASYMMETRIC HYDROGENATION AND METHOD FOR MANUFACTURING OPTICALLY ACTIVE CARBONYL COMPOUND USING THE SAME | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2013-08-22 | — | — | US | disclosed |
| EP-1725542-A1 | VLA-4 ANTAGONISTS | Merck & Co., Inc. (US) | 2006-11-29 | — | — | EP | disclosed |
| WO-2006115918-A2 | VLA-4 ANTAGONISTS | MERCK & CO., INC. (US) | 2006-11-02 | — | — | WO | disclosed |
| WO-2006023396-A2 | VLA-4 ANTAGONISTS | MERCK & CO., INC. (US) | 2006-03-02 | — | — | WO | disclosed |
| US-20050277167-A1 | Prolyl 3-hydroxylases | SHRINERS HOSPITALS FOR CHILDREN | 2005-12-15 | — | — | US | disclosed |
| WO-2005112999-A2 | CANCER TREATMENT WITH INHIBITORS OF COLLAGEN SYNTHESIS | VECTRAMED, INC. (US) | 2005-12-01 | — | — | WO | disclosed |
| WO-2005087760-A1 | VLA-4 ANTAGONISTS | MERCK & CO., INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| EP-1416932-A1 | NEW DIPEPTIDYL PEPTIDASE IV INHIBITORS AND THEIR USES FOR LOWERING BLOOD PRESSURE LEVELS | Probiodrug AG (DE) | 2004-05-12 | — | — | EP | disclosed |
| WO-2003015775-A1 | NEW DIPEPTIDYL PEPTIDASE IV INHIBITORS AND THEIR USES FOR LOWERING BLOOD PRESSURE LEVELS | PROBIODRUG AG (DE) | 2003-02-27 | — | — | WO | disclosed |
| EP-1014945-A1 | CATIONIC LIPID COMPOSITIONS TARGETING ANGIOGENIC ENDOTHELIAL CELLS | The Regents of the University of California (US) | 2000-07-05 | — | — | EP | disclosed |
| WO-1998040052-A1 | CATIONIC LIPID COMPOSITIONS TARGETING ANGIOGENIC ENDOTHELIAL CELLS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1998-09-17 | — | — | WO | disclosed |